# Clinical Trial of Ventiflow LP Supporting High-risk Percutaneous Coronary Intervention(PCI)

Study · id `cardio:ct-nct06754839` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06754839](<https://clinicaltrials.gov/study/NCT06754839>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06754839

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 250 participants.

## Technical summary

Registry record NCT06754839. Randomized; no masking; primary purpose treatment. Start 2024-12 (anticipated); primary completion 2025-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT06754839, source copy `cardio:ctgov-nct06754839-2025-01-01`, retrieved 2026-10-26)
- Planned start: 2024-12 (anticipated) (ClinicalTrials.gov record NCT06754839, source copy `cardio:ctgov-nct06754839-2025-01-01`, retrieved 2026-10-26)
- Primary completion: 2025-10 (anticipated) (ClinicalTrials.gov record NCT06754839, source copy `cardio:ctgov-nct06754839-2025-01-01`, retrieved 2026-10-26)
- Completion: 2025-12 (anticipated) (ClinicalTrials.gov record NCT06754839, source copy `cardio:ctgov-nct06754839-2025-01-01`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06754839-2025-01-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial of Ventiflow LP Supporting High-risk Percutaneous Coronary Intervention(PCI)
- Condition: Coronary Artery Disease
- Condition: Heart Failure
- Condition: High-risk PCI
- Intervention (Device): Percutaneous left ventricular assist device(Ventiflow LP)
- Intervention (Device): VA-ECMO
- Lead sponsor: Suzhou Hearthill Medical Technology Co.,LTD
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 6f06fb8e412d17deffefc969996ee8faaeaf0449d486e9f48afbe38932f86b44
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
